Skip to content

Leukemia Cell Cultures for Research of New Anti-Cancer Therapies

Leukemia Cell Cultures for Research of New Anti-cancer Therapies

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00993538
Enrollment
180
Registered
2009-10-12
Start date
2009-07-31
Completion date
Unknown
Last updated
2011-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Leukaemia

Keywords

Leukaemia, Blood and marrow cells culture, Cell growth, Cell differentiation

Brief summary

The main objective of this project is not only a better understanding of the human leukemic disease but also to find new anti-leukemic or improve existing ones. This study has, the following aims: * To analyze the genetic and epigenetic regulation of the retinoic acid induced cascade which leads to the expression of TRAIL in blood cells of patients with acute leukemia. This study will be complemented by the analysis of global gene expression (DNA chips) and of the DNA methylation state, and by chromatin immunoprecipitation experiences. * To determine the efficiency of inhibitors of enzymes responsible for the modification of chromatin (existing and new developments within the European consortium EPITRON coordinated by Dr Gronemeyer) as inducers of differentiation and / or apoptosis of leukemic blasts. * To explore Ikaros genic and functional abnormalities (genomic deletions, mutations, abnormal transcripts and proteins) in acute leukemia. The aim is to determine if these abnormalities may play a prognosis role.

Interventions

PROCEDUREBlood sampling
PROCEDUREBone marrow aspiration

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
28 Days to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with suspected de novo or secondary or relapsed acute leukemia, requiring complementary blood test and bone marrow analysis * Patients older or equal than 28 days * Informed consent signed

Exclusion criteria

* Pregnancy * Breastfeeding

Countries

France

Contacts

Primary ContactRaoul Herbrecht, MD
Raoul.herbrecht@chru-strasbourg.fr3.33.88.12.83.79
Backup ContactPatrick lutz, MD
Patrick.lutz@chru-strasbourg.fr3.33.88.12.80.90

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026